---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029654"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:46:42.517759+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics: second IDMC review finds VCN-01 well tolerated in metastatic PDAC trial

## Summary
- IDMC reviewed safety data from 101 patients across 14 sites in US and Spain.
- VCN-01 AE profile consistent with prior trials; AEs transient and reversible, less frequent after second dose.
- Patient enrollment completed Sep 2024; topline clinical outcomes data expected Q2 2025.
- CEO says positive data, along with prior FDA/EMA feedback, could guide Phase 3 registrational trial design.

## SEC filing metadata
- accession: 0001104659-25-029654
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/0001104659-25-029654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/tm2510883d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029654
- JSON: https://secwatch.observer/filing/0001104659-25-029654.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.